Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye

A unit dose of a pharmaceutical composition formulated for treating glaucoma in a subject in need thereof;

• wherein the composition comprises an amount of a small-molecule means for selectively inhibiting Bcl-2 or Bcl-xL;
• wherein the unit dose is formulated with an excipient in a volume that is suitable for intraocular administration;
• and
• wherein the formulation of the composition and the amount of the means for selectively inhibiting Bcl-2 or Bcl-xL in the unit dose configure the unit dose to be effective in selectively killing p16 positive senescent cells in the eye that are causing adverse symptoms of the glaucoma in the subject when administered to the subject intraocularly as a single dose, thereby decreasing the severity of the one or more symptoms of glaucoma in the eye of the subject for at least two weeks.

A unit dose of a pharmaceutical composition formulated for treating of an ophthalmic disease or disorder that is not a cancer in an eye of a subject in need thereof;

• wherein the composition comprises an effective amount of the compound (R)—N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5 fluorophenyl)piperazin-1-yl)phenyl)-4-((4-(4-hydroxypiperidin-1-yl)-1-(phenylthio)butan-2 yl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (BM-1197) or a salt thereof,
• wherein the unit dose is formulated with an excipient in a volume suitable for intravitreal administration;
• and
• wherein the formulation of the composition and the amount of the compound in the unit dose configure the unit dose to be effective in treating the ophthalmic disease or disorder in the subject when administered intravitreally to the subject as a single dose.